Ardent Capital Management Inc. Has $11.45 Million Stake in Stryker Co. (NYSE:SYK)

Ardent Capital Management Inc. increased its holdings in shares of Stryker Co. (NYSE:SYK) by 2.4% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 31,804 shares of the medical technology company’s stock after purchasing an additional 755 shares during the period. Stryker accounts for approximately 5.2% of Ardent Capital Management Inc.’s holdings, making the stock its 6th largest position. Ardent Capital Management Inc.’s holdings in Stryker were worth $11,451,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Nicholson Wealth Management Group LLC grew its holdings in Stryker by 63.8% during the fourth quarter. Nicholson Wealth Management Group LLC now owns 4,504 shares of the medical technology company’s stock worth $1,622,000 after purchasing an additional 1,754 shares during the period. Tandem Investment Advisors Inc. boosted its holdings in shares of Stryker by 2.6% during the fourth quarter. Tandem Investment Advisors Inc. now owns 272,938 shares of the medical technology company’s stock worth $98,271,000 after acquiring an additional 6,897 shares during the period. Aspen Investment Management Inc boosted its holdings in shares of Stryker by 2.9% during the fourth quarter. Aspen Investment Management Inc now owns 4,647 shares of the medical technology company’s stock worth $1,673,000 after acquiring an additional 133 shares during the period. Mattern Capital Management LLC boosted its holdings in shares of Stryker by 2.0% during the fourth quarter. Mattern Capital Management LLC now owns 26,622 shares of the medical technology company’s stock worth $9,585,000 after acquiring an additional 515 shares during the period. Finally, Boston Financial Mangement LLC boosted its holdings in shares of Stryker by 5.7% during the fourth quarter. Boston Financial Mangement LLC now owns 21,609 shares of the medical technology company’s stock worth $7,780,000 after acquiring an additional 1,162 shares during the period. Institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on SYK. BTIG Research boosted their price objective on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. JPMorgan Chase & Co. boosted their price objective on Stryker from $420.00 to $445.00 and gave the stock an “overweight” rating in a report on Wednesday, January 29th. UBS Group boosted their price objective on Stryker from $366.00 to $370.00 and gave the stock a “neutral” rating in a report on Wednesday, October 30th. Robert W. Baird boosted their price objective on Stryker from $378.00 to $405.00 and gave the stock an “outperform” rating in a report on Wednesday, October 30th. Finally, Morgan Stanley upgraded shares of Stryker from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $370.00 to $445.00 in a research report on Monday, December 2nd. Five investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and an average price target of $420.68.

Stryker Stock Down 0.5 %

Shares of SYK opened at $386.47 on Friday. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a market cap of $147.47 billion, a P/E ratio of 49.80, a P/E/G ratio of 2.93 and a beta of 0.96. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The firm has a 50 day simple moving average of $377.92 and a two-hundred day simple moving average of $368.21.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter in the prior year, the company earned $3.46 earnings per share. Research analysts forecast that Stryker Co. will post 13.49 EPS for the current fiscal year.

Stryker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be given a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.87%. Stryker’s dividend payout ratio is currently 43.30%.

Insider Transactions at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the transaction, the director now owns 3,642,075 shares of the company’s stock, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.